Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

CERTAINTY A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT

Coordinator
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV, Germany
Runs
1 December 2023 to 31 May 2028
Status
Running
EU funding
€10.0m
Total cost
€10.1m
Partners
17 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101136379

What the project is doing

In the project's own words, from its summary on CORDIS.

This project aims to create a multi-scale patient-specific human virtual twin for patients who are eligible for CAR T cell therapy, which can be extended to cellular immunotherapies in general. The virtual twin will be fully integrated into the ecosystem under the Digital Europe Programme and will be available as a research-use-only prototype in relevant application environments with technology readiness level 6. The virtual twin will support decision-making throughout the patient's journey, from diagnosis to pre-treatments, cellular immunotherapy, and late patient monitoring.

This will enable patients and health experts to identify the most effective course of therapy. The virtual twin for cellular immunotherapies will take multi-scale modelling to the next level by providing methodological concepts for integrating ""living drugs"" such as CAR T cells into the human virtual twin ecosystem. To achieve this goal, the project builds on existing data models for hematological malignancies and multiple myeloma (MM) to create a virtual twin for CAR T cell therapy for MM patients.

The implementation process follows software development principles for software as medical devices, ensuring the exploitation of the research-use-only prototype. Patient's, SSH, gender differences, and other stakeholders' perspectives are fully integrated into the design, specification, and implementation process. Throughout the implementation process, a modular software architecture and extensible ontologies/terminologies are utilized, making the reference model easily transferable to other indications that can be treated with CAR T cell therapy or other cellular immunotherapies.

Overall, the CERTAINTY virtual twin will provide decision support for patients and health experts, improving the effectiveness of cellular immunotherapies and advancing precision medicine.""

Topics

Who is involved

OrganisationCityCountryRole
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyCoordinator
Myeloma Patients Europe AisblBruxellesBelgiumParticipant
Universite De NamurNamurBelgiumParticipant
F. Hoffmann-La Roche AGBaselSwitzerlandAssociatedpartner
Masarykova univerzitaBrnoCzechiaParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Collaborate Project Management GmbHMunchenGermanyParticipant
Helmholtz-Zentrum Dresden-Rossendorf eVDresdenGermanyParticipant
Singleron Biotechnologies GmbHCologneGermanyParticipant
Trinetx Oncology GmbHFreiburgGermanyParticipant
Universitaet LeipzigLeipzigGermanyParticipant
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-UniversitatWurzburgGermanyParticipant
Institut CurieParisFranceParticipant
Information Technology for Translational Medicine (ittm) SAEsch-UelzechtLuxembourgParticipant
European Society for Blood and Marrow TransplantationLeidenNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Healthtree Foundation IncLehiUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI